Nissar Ahmed Sheikh1, Mohammed Hassan Khan1, Sanjay Pillai1, Stephen Lang1, Ghulam Nabi2. 1. Academic Urology Unit, Cancer Research Division, Department of Urology, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, DD1 9SY, Scotland, UK. 2. Academic Urology Unit, Cancer Research Division, Department of Urology, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, DD1 9SY, Scotland, UK. g.nabi@dundee.ac.uk.
Abstract
OBJECTIVES: To report longitudinal outcomes of a population-based cohort of patients diagnosed with bilateral small renal masses from a period of over 11 years. PATIENTS AND METHODS: Consecutive patients diagnosed with bilateral small renal masses (synchronous or metachronous) of a defined geographical area were recorded in a large database (TUCAN database) between January 2005 and December 2016. Patients had a unique identifier number and followed during this period using an agreed upon protocol. Clinicopathological characteristics and outcomes of bilateral small renal masses on active surveillance were analysed and compared to propensity score-matched sporadic unilateral small renal masses. Data were analysed for renal mass growth rate, rate of intervention and development of metastatic disease and patient survival. RESULTS: A total of 1060 patients were diagnosed with renal cancer, of which bilateral small renal masses accounted for 70 (6.6%) cases. Synchronous SRMs were observed in 63 patients, whereas metachronous lesions were found in seven patients during the study period. Metachronous lesion mean time to appearance was 62 ± 41 months (range 9-149 months). While most cases were sporadic, four were found to be hereditary. Growth rate of bilateral small renal masses did not differ from that of unilateral sporadic small renal masses. Similarly, there were no differences between the groups for rate of interventions and survival. CONCLUSIONS: Progression, rate of metastases and survival for patients diagnosed with bilateral small renal masses are similar to those diagnosed with unilateral disease.
OBJECTIVES: To report longitudinal outcomes of a population-based cohort of patients diagnosed with bilateral small renal masses from a period of over 11 years. PATIENTS AND METHODS: Consecutive patients diagnosed with bilateral small renal masses (synchronous or metachronous) of a defined geographical area were recorded in a large database (TUCAN database) between January 2005 and December 2016. Patients had a unique identifier number and followed during this period using an agreed upon protocol. Clinicopathological characteristics and outcomes of bilateral small renal masses on active surveillance were analysed and compared to propensity score-matched sporadic unilateral small renal masses. Data were analysed for renal mass growth rate, rate of intervention and development of metastatic disease and patient survival. RESULTS: A total of 1060 patients were diagnosed with renal cancer, of which bilateral small renal masses accounted for 70 (6.6%) cases. Synchronous SRMs were observed in 63 patients, whereas metachronous lesions were found in seven patients during the study period. Metachronous lesion mean time to appearance was 62 ± 41 months (range 9-149 months). While most cases were sporadic, four were found to be hereditary. Growth rate of bilateral small renal masses did not differ from that of unilateral sporadic small renal masses. Similarly, there were no differences between the groups for rate of interventions and survival. CONCLUSIONS: Progression, rate of metastases and survival for patients diagnosed with bilateral small renal masses are similar to those diagnosed with unilateral disease.
Entities:
Keywords:
Active surveillance; Nephrectomy; Renal cancer; Surgery
Authors: Surya P Rednam; Ayelet Erez; Harriet Druker; Katherine A Janeway; Junne Kamihara; Wendy K Kohlmann; Katherine L Nathanson; Lisa J States; Gail E Tomlinson; Anita Villani; Stephan D Voss; Joshua D Schiffman; Jonathan D Wasserman Journal: Clin Cancer Res Date: 2017-06-15 Impact factor: 12.531
Authors: Michael L Blute; Nancy B Itano; John C Cheville; Amy L Weaver; Christine M Lohse; Horst Zincke Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506